Is SLN a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Divesiran and the SANRECO Phase 2 readout, with revenue (ttm) at ~$0.6M (collaboration revenue only, down from ~$42M in FY2024). The bear case rests on silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings. Analysts covering it are spread from $4.00 to $75.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $4.00, -66.5% from the $11.95 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Divesiran and the SANRECO Phase 2 readout. Topline Phase 2 data for divesiran in polycythemia vera is guided for the third quarter of 2026, pulled forward by faster than expected enrollment. The most optimistic analyst target on SLN is $75.00, +527.6% from the $11.95 price. That figure is only reachable if this thesis works close to its best case.

Silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings. A disappointing SANRECO readout would remove the near-term catalyst that drove the share price higher over the past year, and a partner for zerlasiran may not appear on acceptable economics or at all, which would leave the larger asset stranded. Cash of roughly $72 million funds operations into 2028 on the current reduced plan, but the company has acknowledged that later-stage trials require additional capital, and clinical-stage biotechs typically raise that capital by issuing stock, which dilutes existing holders. Competition is well funded on both fronts: several large pharmaceutical companies are running Phase 3 lipoprotein(a) programs, and polycythemia vera already has approved and late-stage alternatives. Because the ADSs represent three ordinary shares each, per-share figures quoted for the Nasdaq listing and the underlying UK share count are not directly comparable, which is a frequent source of confusion when reading coverage. The most pessimistic published target is $4.00, -66.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Silence Therapeutics is a UK clinical-stage biotech whose Nasdaq-listed ADSs back two siRNA programs: zerlasiran for lipoprotein(a) and divesiran for polycythemia vera.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Divesiran and the SANRECO Phase 2 readout) stalling in the reported numbers rather than in the narrative, the risk above (silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It designs short interfering RNA drugs that shut off production of a specific protein in liver cells before that protein is ever made. Its mRNAi GOLD platform attaches a GalNAc sugar to the siRNA so the liver absorbs it after a simple injection. The two lead candidates are zerlasiran for high lipoprotein(a) and divesiran for polycythemia vera.

Yes. Silence Therapeutics plc is a UK company, and what trades on Nasdaq under SLN is an American Depositary Share representing 3 ordinary shares. Roughly 141.7 million ordinary shares were outstanding as of April 30, 2026, which corresponds to about 47 million ADSs. Any per-share figure sourced from the UK filings needs to be multiplied by three before it can be compared with the Nasdaq quote.

Almost none. Trailing twelve-month revenue is roughly $0.6 million, all of it collaboration revenue recognized from the AstraZeneca agreement, down from about $42.5 million in fiscal 2024 when partnership milestones were flowing. The company has no approved product and no product sales, so the drop reflects the timing of partnership accounting rather than a business that shrank.